drugset / Trial / NCT04782128
Evaluation of RC28-E Injection in Diabetic Retinopathy
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, open-label, multicenter study of the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) in the treatment of patients with moderately severe to severe nonproliferative diabetic retinopathy.
Timeline
- Start
- 2021-05-25
- Primary completion
- 2024-05
- Completion
- 2024-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RC28-E | Protein / enzyme biologic | 1 mg | Intravitreal |
| Subject | RC28-E | Protein / enzyme biologic | 2 mg | Intravitreal |